- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 167
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
- Interventions
- Etanercept, Mifepristone
- Drug
- Lead sponsor
- South Florida Veterans Affairs Foundation for Research and Education
- Federal
- Eligibility
- 40 Years to 70 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Arthritis, Rheumatoid
- Interventions
- tofacitinib, adalimumab, etanercept
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
- Conditions
- Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
- Interventions
- Etanercept, Placebo
- Drug
- Lead sponsor
- Michael Portman
- Other
- Eligibility
- 2 Months to 20 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 7
- States / cities
- New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
- Conditions
- Psoriasis
- Interventions
- Etanercept, Placebo injections
- Biological · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
- Conditions
- Tumors
- Interventions
- Etanercept, Docetaxel, Dexamethasone
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Psoriasis
- Interventions
- Guselkumab, Placebo for guselkumab, Etanercept
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 10
- States / cities
- Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- GP2015
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 26
- States / cities
- Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- no intervention
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
- Other · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tofacitinib, TNF Inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20,167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2030
- U.S. locations
- 167
- States / cities
- Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Placebo, secukinumab (AIN457), etanercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
- Conditions
- Type 1 Diabetes, Hypoglycemia
- Interventions
- Allogeneic islets of Langerhans transplant
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Plaque Psoriasis.
- Interventions
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Graft Versus Host Disease
- Interventions
- stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity
- Interventions
- Etanercept Optimal dosing
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 2 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rheumatoid Arthritis
- Interventions
- Baricitinib, TNF Inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 81
- States / cities
- Flagstaff, Arizona • Gilbert, Arizona • Glendale, Arizona + 69 more
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
- Interventions
- Tildrakizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 6 Years to 215 Months
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 5
- States / cities
- Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis
- Interventions
- Etanercept / Autoinjector A
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Infliximab
- Biological
- Lead sponsor
- Centocor Ortho Biotech Services, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
- Conditions
- Psoriasis
- Interventions
- etanercept
- Biological
- Lead sponsor
- Florida Academic Dermatology Centers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida